Teacher Retirement System of Texas Increases Stock Position in Moderna, Inc. $MRNA

Teacher Retirement System of Texas raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.7% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 93,662 shares of the company’s stock after buying an additional 4,166 shares during the period. Teacher Retirement System of Texas’ holdings in Moderna were worth $2,584,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in MRNA. Probity Advisors Inc. raised its holdings in Moderna by 2.6% in the 2nd quarter. Probity Advisors Inc. now owns 14,892 shares of the company’s stock worth $411,000 after purchasing an additional 377 shares in the last quarter. Blue Sky Capital Consultants Group Inc. raised its holdings in Moderna by 3.8% in the 1st quarter. Blue Sky Capital Consultants Group Inc. now owns 15,119 shares of the company’s stock worth $429,000 after purchasing an additional 556 shares in the last quarter. Nissay Asset Management Corp Japan ADV raised its holdings in Moderna by 1.4% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 40,639 shares of the company’s stock worth $1,152,000 after purchasing an additional 562 shares in the last quarter. Empirical Finance LLC raised its holdings in Moderna by 7.3% in the 1st quarter. Empirical Finance LLC now owns 9,215 shares of the company’s stock worth $261,000 after purchasing an additional 624 shares in the last quarter. Finally, Xponance Inc. raised its holdings in Moderna by 1.4% in the 1st quarter. Xponance Inc. now owns 45,412 shares of the company’s stock worth $1,287,000 after purchasing an additional 642 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Leerink Partners decreased their price objective on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a report on Friday, August 22nd. Wells Fargo & Company restated an “equal weight” rating on shares of Moderna in a report on Sunday, July 13th. Cowen assumed coverage on shares of Moderna in a report on Sunday, July 13th. They issued a “hold” rating for the company. JPMorgan Chase & Co. decreased their price objective on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a report on Thursday, October 23rd. Finally, UBS Group decreased their price objective on shares of Moderna from $70.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $36.86.

Moderna Price Performance

Shares of Moderna stock opened at $27.16 on Monday. The company has a 50-day moving average of $25.86 and a 200 day moving average of $27.18. The firm has a market cap of $10.61 billion, a price-to-earnings ratio of -3.61 and a beta of 2.02. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $56.69.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna’s quarterly revenue was down 41.1% compared to the same quarter last year. During the same period last year, the business earned ($3.33) EPS. On average, equities analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.